Nuwellis, Inc.
NUWE Nasdaq Electromedical & Electrotherapeutic Apparatus Financials FY2016βFY2025
What Nuwellis, Inc. does
No business description yet.
- Legal name
- Nuwellis, Inc.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K Β· Mar 11, 2026
- Accession Β· CIK
- 0001140361-26-009080
0001506492
Revenue and margins
Nuwellis, Inc. had $8.3M of revenue in fiscal 2025, down 5.4% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was β$10.9M in fiscal 2025, β131.8% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Nuwellis, Inc. returned β to shareholders in fiscal 2025. The diluted share count rose 2,083.9%.
Balance sheet
Cash, debt and the ratios that show how comfortably Nuwellis, Inc. can carry it.
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | $24.2M | $18.3M | $3.8M | $5.1M | $1.1M |
| Current ratio | 8.5x | 4.9x | 2.6x | 3.5x | 1.7x |
| Quick ratio | 7.6x | 4.3x | 2.0x | 2.8x | 1.1x |
| Total assets | $30.4M | $24.7M | $9.8M | $9.9M | $6.1M |
| Total liabilities | $4.5M | $12.3M | $6.6M | $3.3M | $3.5M |
| Shareholders' equity | $25.9M | $12.4M | $3.0M | $6.5M | $2.6M |
| Net debt (β = net cash) | β | β | β | β | β |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. 'Plan' marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
β
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8β9 is strong, 0β2 weak.
| Test | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Net income is positive | β | β | β | β | β | β | β | β | β | β |
| Cash from operations is positive | β | β | β | β | β | β | β | β | β | β |
| Return on assets rose | β | β | β | β | β | β | β | β | β | β |
| Cash from operations exceeds net income | β | β | β | β | β | β | β | β | β | β |
| Debt fell relative to assets | β | β | β | β | β | β | β | β | β | β |
| Current ratio rose | β | β | β | β | β | β | β | β | β | β |
| Share count didn't rise | β | β | β | β | β | β | β | β | β | β |
| Gross margin rose | β | β | β | β | β | β | β | β | β | β |
| Revenue rose relative to assets | β | β | β | β | β | β | β | β | β | β |
| F-score | β / 3 | 4 / 8 | 3 / 8 | 4 / 8 | 3 / 8 | 5 / 8 | 2 / 8 | 4 / 8 | 5 / 8 | 2 / 8 |
| Accruals ratio | 6.7% | β11.3% | β18.2% | β24.3% | 5.7% | β6.8% | 2.3% | β13.2% | β16.0% | β84.0% |
| Altman Z'' | β88.21 | β24.31 | β80.96 | β146.91 | β34.19 | β19.97 | β34.15 | β104.24 | β99.99 | β177.65 |
10 years of figures
US$ millions unless stated. Hover a ratio's name for its definition.
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | $1.3M | $3.6M | $5.0M | $5.5M | $7.4M | $7.9M | $8.5M | $8.9M | $8.7M | $8.3M |
| Gross profit | $0.6M | $0.8M | $1.3M | $2.9M | $4.1M | $4.5M | $4.8M | $5.0M | $5.7M | $5.1M |
| Research and development | $8.1M | $1.5M | $3.1M | $4.7M | $3.7M | $5.0M | $4.3M | $5.4M | $3.2M | $2.7M |
| Operating income | β$15.7M | β$14.8M | β$17.0M | β$18.1M | β$17.0M | β$19.5M | β$17.2M | β$17.6M | β$11.0M | β$11.1M |
| Interest expense | $0.5M | β | β | β | β | β | β | β | β | β |
| Pretax income | β$15.8M | β$13.4M | β$17.0M | β$18.1M | β$15.8M | β$19.5M | β$14.5M | β$20.2M | β$11.2M | β$17.5M |
| Income tax | β$0.1M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Net income | β$15.8M | β$13.4M | β$17.0M | β$18.1M | β$15.8M | β$19.6M | β$14.5M | β$20.2M | β$11.2M | β$17.5M |
| Net income to common | β$17.7M | β$25.0M | β$17.0M | β$22.6M | β$17.6M | β$19.6M | β$14.5M | β$22.6M | β$10.6M | β$17.5M |
| Diluted EPS | β$536.12 | β$525.01 | β$42.14 | β$278.90 | β$10.67 | β$285.36 | β$83.55 | β$360.06 | β$353.30 | β$25.39 |
| Diluted shares | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B | 0.00B |
| Cash flow | ||||||||||
| Cash from operations | β$16.3M | β$11.9M | β$14.6M | β$16.4M | β$16.6M | β$17.8M | β$15.1M | β$17.9M | β$9.6M | β$10.8M |
| Capital expenditure | $0.1M | $0.3M | $0.2M | $0.5M | $0.3M | $0.2M | $0.1M | $0.1M | $0.1M | $0.1M |
| Free cash flow | β$16.4M | β$12.2M | β$14.8M | β$16.9M | β$16.9M | β$18.1M | β$15.3M | β$18.1M | β$9.7M | β$10.9M |
| Depreciation and amortization | $0.7M | $0.8M | $0.2M | $0.2M | $0.4M | $0.5M | $0.4M | $0.4M | $0.3M | $0.2M |
| Stock-based compensation | $0.9M | $0.5M | $2.1M | $1.5M | $1.3M | $1.3M | $0.9M | $0.7M | $0.5M | $0.1M |
| Acquisitions | $4.0M | $0.0M | β | β | β | β | β | β | β | β |
| Balance sheet | ||||||||||
| Cash and short-term investments | $1.3M | $15.6M | $5.5M | $1.3M | $14.4M | $24.2M | $18.3M | $3.8M | $5.1M | $1.1M |
| Finance lease liabilities | β | β | β | β | $0.1M | β | β | β | β | β |
| Current assets | $2.4M | $17.9M | $8.1M | $4.0M | $18.5M | $28.1M | $22.8M | $8.2M | $8.9M | $5.2M |
| Current liabilities | $3.3M | $2.1M | $2.8M | $3.4M | $3.6M | $3.3M | $4.7M | $3.2M | $2.6M | $3.0M |
| Inventory | $0.7M | $1.6M | $1.7M | $1.8M | $3.0M | $2.8M | $2.7M | $2.0M | $1.7M | $1.9M |
| Property and equipment, net | $0.5M | $0.6M | $0.5M | $1.0M | $1.2M | $1.2M | $1.0M | $0.7M | $0.5M | $0.4M |
| Goodwill | $0.2M | $0.0M | β | β | β | β | β | β | β | β |
| Intangible assets | $4.3M | $0.0M | β | β | β | β | β | β | β | $0.0M |
| Total assets | $7.5M | $18.5M | $8.8M | $5.6M | $20.0M | $30.4M | $24.7M | $9.8M | $9.9M | $6.1M |
| Total liabilities | $5.2M | $2.2M | $2.8M | $3.6M | $3.7M | $4.5M | $12.3M | $6.6M | $3.3M | $3.5M |
| Preferred stock | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M | $0.0M |
| Shareholders' equity | $1.8M | $16.2M | $5.9M | $2.0M | $16.3M | $25.9M | $12.4M | $3.0M | $6.5M | $2.6M |
| Margins | ||||||||||
| Gross margin | 44.7% | 22.2% | 26.6% | 51.7% | 54.5% | 56.7% | 55.7% | 56.2% | 64.9% | 62.0% |
| Operating margin | β1,215.1% | β416.9% | β340.9% | β328.5% | β228.8% | β246.5% | β201.0% | β198.9% | β125.7% | β134.3% |
| EBITDA margin | β1,161.0% | β395.2% | β336.2% | β324.2% | β223.8% | β240.3% | β196.6% | β194.8% | β122.2% | β131.9% |
| Net margin | β1,225.1% | β376.6% | β340.8% | β328.7% | β212.8% | β246.9% | β170.0% | β228.0% | β127.7% | β211.9% |
| FCF margin | β1,273.0% | β342.8% | β295.3% | β305.9% | β226.7% | β228.0% | β178.8% | β204.0% | β110.4% | β131.8% |
| Returns | ||||||||||
| Return on capital employed | β371.9% | β90.5% | β287.0% | β804.4% | β103.7% | β72.0% | β85.9% | β267.2% | β150.4% | β359.9% |
| Return on equity | β898.8% | β148.7% | β153.6% | β457.1% | β173.0% | β92.5% | β75.8% | β263.4% | β234.6% | β382.9% |
| Return on assets | β211.4% | β103.2% | β125.1% | β252.0% | β123.7% | β77.6% | β52.7% | β117.3% | β113.7% | β219.3% |
| Return on tangible equity | β | β153.8% | β286.9% | β1,136.8% | β107.8% | β75.6% | β117.5% | β756.8% | β162.7% | β667.6% |
| Growth | ||||||||||
| Revenue growth | β | 175.6% | 40.7% | 10.3% | 35.0% | 6.5% | 7.9% | 3.8% | β1.4% | β5.4% |
| Share count change | β | 45.5% | 741.7% | β80.0% | 1,935.8% | β95.8% | 151.9% | β67.7% | β43.7% | 2,083.9% |
| Financial health | ||||||||||
| Interest coverage | β31.1x | β | β | β | β | β | β | β | β | β |
| Current ratio | 0.7x | 8.5x | 2.9x | 1.2x | 5.2x | 8.5x | 4.9x | 2.6x | 3.5x | 1.7x |
| Quick ratio | 0.5x | 7.8x | 2.3x | 0.7x | 4.3x | 7.6x | 4.3x | 2.0x | 2.8x | 1.1x |
| Capital allocation | ||||||||||
| Capex / revenue | 9.1% | 7.3% | 4.0% | 8.9% | 4.0% | 2.8% | 1.4% | 1.7% | 0.7% | 1.1% |
| Stock comp / revenue | 73.6% | 14.0% | 41.8% | 27.4% | 18.1% | 16.6% | 10.1% | 7.6% | 5.5% | 1.5% |
| Quality scores | ||||||||||
| Piotroski F-score | β | 4.0 | 3.0 | 4.0 | 3.0 | 5.0 | 2.0 | 4.0 | 5.0 | 2.0 |
| Altman Z'' | β88.2 | β24.3 | β81.0 | β146.9 | β34.2 | β20.0 | β34.1 | β104.2 | β100.0 | β177.6 |
| Accruals ratio | 6.7% | β11.3% | β18.2% | β24.3% | 5.7% | β6.8% | 2.3% | β13.2% | β16.0% | β84.0% |
Source: SEC EDGAR XBRL filings (CIK 0001506492). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only β not investment advice. Check the original filings before relying on any figure.